Popular search terms:
Search Results
19 results found-
Data Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec) Over Five Years
https://www.cslbehring.de/en-us/news/2025/pm-hemgenix-long-term-durability-safety -
First Patient Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Haemophilia B in Germany
https://www.cslbehring.de/en-us/news/2025/pm-hemgenix-erster-patient-deu -
First Patient Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Haemophilia B in Austria
https://www.cslbehring.de/news/2025/pm-hemgenix-first-patient-at -
First patients treated with HEMGENIX® (etranacogene dezaparvovec) gene therapy for haemophilia B in Denmark
https://www.cslbehring.de/news/2025/pm-hemgenix-first-patients-denmark -
Get to know us and learn more about people, projects and what happens in the world of CSL Behring.
https://www.cslbehring.de/en-us/news/2023 -
CSL Behring Signs Milestone Commercial Agreement with Amgros to Fund Haemophilia B Gene Therapy HEMGENIX® in Denmark
https://www.cslbehring.de/en-us/news/2024/pm-agreement-amgros-denmark -
Get to know us and learn more about people, projects and what happens in the world of CSL Behring.
https://www.cslbehring.de/en-us/news/2021 -
CSL Behring granted positive reimbursement recommendation for Haemophilia B Gene Therapy, HEMGENIX® in Spain
https://www.cslbehring.de/en-us/news/2024/pm-hmgenix-reimbursement-spain -
Information on the terms and conditions of use of the CSL Behring Germany website.
https://www.cslbehring.de/en-us/terms-of-use -
Lernen Sie uns kennen und erfahren Sie mehr über Menschen, Projekte und was in der Welt von CSL Behring passiert.
https://www.cslbehring.de/news/2025